Three months after Biogen finalized its substantial $5.6 billion acquisition of Apellis Pharmaceuticals, a significant shift in research and development…
Read More

Three months after Biogen finalized its substantial $5.6 billion acquisition of Apellis Pharmaceuticals, a significant shift in research and development…
Read More
The American Society of Gene & Cell Therapy (ASCGT) and Orphan Therapeutics Accelerator (OTXL) have officially unveiled CGTxchange, an innovative,…
Read More
In a strategic move to enhance precision in oncology drug development, Japanese pharmaceutical giant Daiichi Sankyo has announced a significant…
Read More